He spent 25 years learning how drugs get made at Baxter, Baxalta, Actelion and Johnson & Johnson. Then he joined a 31-person San Diego startup trying to make that whole process more like engineering than luck.
There is a moment in most venture careers where you sit across the table from a founder, listen to the pitch, decide the science is real, and write the check. Then you go back to your fund and look for the next one. Serge Messerlian did all of that with Creyon Bio. He just could not stop thinking about it afterward. So instead of moving on to the next deal, he moved into the corner office.
By April 2025 he was the company's Chairman and Chief Executive Officer. He had already spent the previous fall as Executive Chairman and Acting CEO, having joined Creyon's board as an investor and board member through DCVC Bio in 2024. The path from writing a check to running the company is not a common one in biotech, where founders and financiers usually keep to their own lanes. Messerlian crossed the line on purpose.
To understand why, it helps to look at what he was walking away from and what he was walking toward.
Messerlian has more than 25 years in the life sciences, and the roles are not small. He was President of Janssen Oncology, the cancer division of Johnson & Johnson, where he set strategic direction for brands and pipeline programs across hematology and solid tumors, including cell therapy platforms. Before Creyon, he was CEO of Teon Therapeutics, an immuno-oncology biotech he helped build. Earlier, he held executive leadership roles at Johnson & Johnson's Actelion, at Baxalta, and at Baxter International, covering M&A integration, business development, product development, and the oversight of multi-billion-dollar operations.
That is a career built at scale. Baxter, Baxalta, Actelion, Janssen: these are names attached to big operations, big budgets, and big org charts. When someone with that background chooses a 31-person startup on Merryfield Row in San Diego's Torrey Pines corridor, it is worth asking what the smaller room offers that the bigger ones did not.
Creyon Bio's premise is that drug design should behave more like engineering. The company builds AI models that predict how oligonucleotides - short strands of engineered genetic material - will behave in the body, aiming to design for both efficacy and safety before a molecule is ever synthesized. The traditional path leans heavily on trial, error, and animal testing. Creyon's pitch is that a lot of that guesswork can be moved upstream into software.
The keyword Messerlian's world keeps circling is predicted instead of discovered. Drug safety, historically, is something you find out about. Creyon wants it to be something you can forecast. For an operator who spent decades watching promising molecules stumble late and expensive, that reframing has obvious appeal.
Sometimes a company's thesis and the regulatory calendar line up in a way that no founder could have scheduled. When Messerlian took the CEO title, the FDA had recently signaled a move to phase out mandatory animal testing in favor of what regulators call new approach methodologies. A platform built to predict biological behavior in silico is, conveniently, exactly the kind of tool that fits a world with less mandatory animal testing.
He did not build the platform to match the policy. But an operator's job is to notice when the wind changes and set the sails accordingly, and this is a clean example of it.
Messerlian's training reads like someone who decided early not to choose between the lab and the boardroom. He holds a bachelor's degree in physiology and biotechnology and a master's in human genetics, both from McGill University in Montreal, and an MBA from the University of Toronto's Rotman School of Management. The science degrees explain why he can sit in a room full of researchers and follow the argument. The MBA explains why he can then translate that argument into a plan a board will fund.
Relative emphasis across his roles, based on public bios. Illustrative, not a metric.
Look at the sequence and a pattern shows up that is easy to miss title by title. Big pharma to biotech. Investor to operator. Established platforms to unproven ones. At almost every fork, Messerlian moved toward the frontier rather than away from it. The safe move for a former Janssen president is another large, stable role. The move he keeps making is the earlier-stage, higher-variance one.
It is a résumé that could read as restless, but the disease areas and the through-question stay consistent. Serve patients, build value, and shorten the distance between an idea and a medicine. Creyon is the version of that question where the shortening happens in code.
The near-term story is a countdown. Creyon has said it aims to move into clinical development in 2026, with a lead program that turns the platform's promise into a molecule a person can actually receive. That is the moment the thesis meets reality. Software can predict a great deal, but a first-in-human study is where predictions get graded.
For Messerlian, it is also the reason the smaller room made sense. At a large company, a single program is one of many. At Creyon, the clinical entry is the whole company's proof point, and he is the person answerable for it. He traded scale for stakes. Given the pattern in the rest of his career, that looks less like a gamble and more like the choice he has been making all along.
The investor decided to run the company. Now he has to build the thing he backed.